- Home
- AVTX vs ALXO Comparison
AVTX vs ALXO Comparison
Compare AVTX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- ALXO
- Stock Information
- Founded
- AVTX 2011
- ALXO 2015
- Country
- AVTX United States
- ALXO United States
- Employees
- AVTX N/A
- ALXO N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- ALXO Health Care
- Exchange
- AVTX Nasdaq
- ALXO Nasdaq
- Market Cap
- AVTX 88.4M
- ALXO 76.5M
- IPO Year
- AVTX 2015
- ALXO 2020
- Fundamental
- Price
- AVTX $8.46
- ALXO $0.66
- Analyst Decision
- AVTX Strong Buy
- ALXO Strong Buy
- Analyst Count
- AVTX 7
- ALXO 6
- Target Price
- AVTX $34.33
- ALXO $4.14
- AVG Volume (30 Days)
- AVTX 109.6K
- ALXO 1.4M
- Earning Date
- AVTX 05-12-2025
- ALXO 03-06-2025
- Dividend Yield
- AVTX N/A
- ALXO N/A
- EPS Growth
- AVTX N/A
- ALXO N/A
- EPS
- AVTX N/A
- ALXO N/A
- Revenue
- AVTX $441,000.00
- ALXO N/A
- Revenue This Year
- AVTX N/A
- ALXO N/A
- Revenue Next Year
- AVTX N/A
- ALXO N/A
- P/E Ratio
- AVTX N/A
- ALXO N/A
- Revenue Growth
- AVTX N/A
- ALXO N/A
- 52 Week Low
- AVTX $5.99
- ALXO $0.65
- 52 Week High
- AVTX $22.47
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- AVTX 56.89
- ALXO 33.23
- Support Level
- AVTX $7.88
- ALXO $0.65
- Resistance Level
- AVTX $9.00
- ALXO $0.74
- Average True Range (ATR)
- AVTX 0.81
- ALXO 0.07
- MACD
- AVTX 0.12
- ALXO -0.00
- Stochastic Oscillator
- AVTX 54.41
- ALXO 0.54
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.